Market Overview

Credit Suisse Raises Eli Lilly Price Target

Related LLY
Zymeworks: Early But Compelling Data, Large Biopharma Partners And A Potential June Catalyst
Watch These 5 Huge Put Purchases In Wednesday Trade

Here are three takeaways on Credit Suiss's price target increase of Eli Lilly and Co (NYSE: LLY).

"1. We raise our target price to $65 (from $61).

2. Raising TP Following 3Q 2014, Remain Neutral While Watching Commercial Execution

3. We maintain our Neutral rating on the stock given the stock’s current valuation and look for successful commercial execution of new product launches, most notably Trulicity (dulaglutide)."

Shares of Eli lilly were up fractionally on average volume at $66.48.

Benzinga Color is embargoed from Benzinga Pro. The content above is delayed by 1.5 hours.

To get it live, subscribe to Benzinga Pro.

Latest Ratings for LLY

Apr 2017Argus ResearchDowngradesBuyHold
Apr 2017BMO CapitalDowngradesMarket PerformUnderperform
Apr 2017Morgan StanleyDowngradesOverweightEqual-Weight

View More Analyst Ratings for LLY
View the Latest Analyst Ratings

Posted-In: Credit SuisseAnalyst Color Price Target Analyst Ratings


Related Articles (LLY)

View Comments and Join the Discussion!